CD274 and neoplasm: Similar to the results obtained in preclinical tumor models described above, myeloid-driven inflammation in tumors appeared to be a resistance mechanism to anti-PD-L1 monotherapy in mRCC which could be overturned by bevacizumab (87, 116, 117).